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Abstract. 
 
Previous studies on the role of microtubule-
associated protein 1B (MAP1B) in adapting microtu-
bules for nerve cell-specific functions have examined 
the activity of the entire MAP1B protein complex con-
sisting of heavy and light chains and revealed moderate 
effects on microtubule stability. Here we have analyzed 
the effects of the MAP1B light chain in the absence or 
presence of the heavy chain by immunofluorescence 
microscopy of transiently transfected cells. Distinct 
from all other MAPs, the MAP1B light chainÐinduced 
formation of stable but apparently flexible microtu-
bules resistant to the effects of nocodazole and taxol. 
Light chain activity was inhibited by the heavy chain. In 
addition, the light chain was found to harbor an actin 
filament binding domain in its COOH terminus. By 
coimmunoprecipitation experiments using epitope-
tagged fragments of MAP1B we showed that light 
chains can dimerize or oligomerize. Furthermore, we 
localized the domains for heavy chainÐlight chain inter-
action to regions containing sequences homologous to 
MAP1A. Our findings assign several crucial activities 
to the MAP1B light chain and suggest a new model for 
the mechanism of action of MAP1B in which the heavy 
chain might act as the regulatory subunit of the 
MAP1B complex to control light chain activity.
Key words: microtubule-associated protein 1B ¥ mi-
crotubules metabolism ¥ nocodazole ¥ actin stress fi-
bers ¥ cytoskeleton
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icrotubule-associated
 
 protein 1B (MAP1B)
 
1
 
was originally identified as a 320-kD protein
that copurified with microtubules from mamma-
lian brain through successive cycles of temperature-depen-
dent polymerization and depolymerization (Greene et al.,
1983; Binder et al., 1984; Bloom et al., 1984; Calvert and
Anderton, 1985; Herrmann et al., 1985; Riederer et al.,
1986). MAP1B is expressed at its highest levels in the
brain during early postnatal development (Binder et al.,
1984; Calvert and Anderton, 1985; Lewis et al., 1986; Ried-
erer et al., 1986; Safaei and Fischer, 1989; Schoenfeld et al.,
1989; Garner et al., 1990). In rodents, expression peaks a
few days after birth and then gradually declines to reach
adult levels. This pattern of expression is reciprocal to that
of the related high molecular mass protein MAP1A, the
expression of which is low at birth and increases during
postnatal development (Schoenfeld et al., 1989; Garner et
al., 1990). In the adult, MAP1B expression remains ele-
vated in brain regions that retain a high level of axonal
growth and synaptic plasticity (Schoenfeld et al., 1989;
Tucker et al., 1989; Nothias et al., 1996). Detailed immu-
nohistochemical analysis revealed that MAP1B is present
in axons, cell bodies, and dendrites of neurons and in glial
cells (Bloom et al., 1985; Calvert and Anderton, 1985;
Riederer et al., 1986; Garner et al., 1989; Schoenfeld et al.,
1989) and immunoelectron microscopy suggested that
MAP1B is a component of a microtubule-associated fibril-
lar matrix found in axons (Hirokawa et al., 1985). Studies
using monoclonal antibodies specific to phosphorylated
MAP1B demonstrated that the protein is differentially
phosphorylated on several sites depending on its expres-
sion in neurons or glial cells, its subcellular localization in
neurons, and the developmental stage (Sato-Yoshitake et
al., 1989; Gordon-Weeks et al., 1993; Harrison et al., 1993;
Riederer et al., 1993; Ulloa et al., 1994; Boyne et al., 1995).
Analyses carried out on differentiating neurons in cell cul-
ture showed that MAP1B levels and phosphorylation are
particularly high in distal axons (Tanaka et al., 1992; Black
et al., 1994; Boyne et al., 1995; Bush et al., 1996). Taken to-
gether, these findings led to the hypothesis that the protein
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might be involved in neuronal differentiation, regulating
microtubule-dynamics in the growing axon.
Cloning of mouse, rat and human MAP1B cDNA re-
vealed highly conserved open reading frames (90% amino
acid identity) of 
 
z
 
2,460 codons, the exact length depend-
ing on the species (Noble et al., 1989; Zauner et al., 1992;
Lien et al., 1994; Liu and Fischer, 1996). Among the high-
est conserved regions of the protein are the NH
 
2
 
-terminal
550 and the COOH-terminal 120 amino acids (98 and
100% identity between mouse and human, respectively).
In addition, MAP1B contains regions of homology to the
distantly related protein MAP1A (Langkopf et al., 1992).
The two main stretches of homology comprise 300 and 120
amino acids and are located in the conserved NH
 
2
 
 and
COOH termini, respectively. MAP1B mRNA is translated
to give rise to a polyprotein that is subsequently cleaved
into two proteins comprising the NH
 
2
 
-terminal 2,200
amino acids, termed the heavy chain, and the COOH-ter-
minal 250 amino acids, termed the light chain of MAP1B
(Hammarback et al., 1991). The exact site where the
polyprotein precursor is cleaved is not known but has been
narrowed down to a region of 
 
z
 
20 amino acids around
amino acid 2,200. Heavy chain and light chain form a com-
plex. The binding site for the light chain has been mapped
to a 120 kD region comprising the NH
 
2
 
-terminal half of
the heavy chain (Kuznetsov et al., 1986; Hammarback et
al., 1991). A similar post-translational proteolytic process-
ing has been observed for MAP1A (Langkopf et al., 1992).
Consistent with the observed pattern of MAP1B expres-
sion during brain development, the protein appears to play
an important role in neuronal differentiation. The first
such evidence was obtained by antisense oligonucleotide
approaches and showed that ablation of MAP1B expres-
sion in PC12 cells or cultured cerebellar macroneurons in-
hibits or reduces neurite outgrowth (Brugg et al., 1993; Di-
Tella et al., 1996). More recently, the phenotypic effects of
homozygous MAP1B mutations introduced into the germ-
line of mice by homologous recombination were investi-
gated in two independent studies (Edelmann et al., 1996;
Takei et al., 1997). Despite discrepancies concerning the
severity of the effects of MAP1B mutations both studies
demonstrated that MAP1B mutations can lead to an im-
pairment or retardation of brain development. However,
the molecular function of MAP1B during neuronal mor-
phogenesis and its mechanism of action remain unclear
and information about functional domains of the protein is
limited to the characterization of the two microtubule-
binding domains. One of these domains is located on the
heavy chain between amino acids 580 to 800 and was iden-
tified by expressing MAP1B mutant proteins containing or
missing this domain in tissue culture cells (Noble et al.,
1989) and by cosedimentation assays in vitro (Zauner et
al., 1992). The other microtubule-binding domain is lo-
cated on the light chain in the region spanning amino acids
2,215 to 2,335 (numbering according to the polyprotein
precursor) and was identified by analyzing the capacity of
recombinant MAP1B fragments synthesized in bacteria to
cosediment with microtubules in vitro (Zauner et al.,
1992).
One approach successfully used to unravel the function
of neuronal MAPs has been the expression of these pro-
teins in nonneuronal cells. However, unlike MAP2, which
induces dramatic effects such as microtubule bundling,
stiffening and stabilization when expressed in nonneu-
ronal cells (Lewis et al., 1989; Takemura et al., 1992; Weis-
shaar et al., 1992; LeClerk et al., 1993; Weisshaar and Ma-
tus, 1993), MAP1B expression induces only modest effects
(Noble et al., 1989; Takemura et al., 1992). MAP1B causes
less efficient stabilization of microtubules than MAP2 and
does not induce microtubule bundling. Likewise, MAP1B
causes microtubule stabilization and nucleation in vitro
but again, less efficiently than MAP2 (Vandecandelaere et
al., 1996). In all these studies the effects of the entire
MAP1B protein complex consisting of heavy and light
chain were analyzed. Here we attempted to investigate
possible effects of the MAP1B light chain on its own to de-
termine which activities, if any, it might have. We chose to
express the light chain or light chain deletion mutants
in nonneuronal cells expressing little or no endogenous
MAP1B to minimize possible interference by the endoge-
nous MAP1B heavy chain. We found that in the absence
of heavy chain the light chain has dramatic and unique ef-
fects on microtubules. We identified for the first time light
chain domains for microtubule stabilization and actin fila-
ment binding, obtained evidence for light chain oligomer-
ization and determined the importance of the MAP1A ho-
mology domains of MAP1B for oligomerization and heavy
chainÐlight chain interaction. Our findings suggest a new
model for MAP1B as a protein complex consisting of a
regulatory subunit, the heavy chain, and an active subunit,
the light chain.
 
Materials and Methods
 
cDNA Constructs
 
The full-length rat MAP1B cDNA was obtained as described (Zauner et
al., 1992; Tgel et al., 1998). Constructs encoding full-length MAP1B
polyprotein precursor (amino acids 1Ð2,459), heavy chain (amino acids
1Ð2,185), light chain (amino acids 2,210Ð2,459), NH
 
2
 
 terminus (amino ac-
ids 1Ð508), COOH terminus (amino acids 2,336Ð2,459), or the microtubule
binding domain of the light chain (amino acids 2,210Ð2,336; see Fig. 1) all
fused in frame to a COOH-terminal myc-tag (amino acid sequence: EQK-
LISEEDLN; Cravchik and Matus, 1993) by a variable linker of 1Ð3 amino
acids containing unique restriction sites were generated using convenient
restriction sites and adapter oligonucleotides. All constructs were cloned
into the Tet-Off expression vector pUHD10-3 (Gossen and Bujard, 1992).
Hemagglutinin (HA)-tagged constructs were obtained by exchanging the
myc-tag against a triple HA-tag (amino acid sequence: ASRYPYDVP-
DYAGYPYDVPDYAGSYPYDVPDYASR; Field et al., 1988) flanked
by appropriate restriction sites. For constructs encoding untagged full-
length MAP1B or untagged light chain the myc-tagged COOH terminus
was replaced by the untagged COOH terminus from the original cDNA
(Zauner et al., 1992; Tgel et al., 1998).
 
Antibodies
 
A rabbit polyclonal anti-light chain antiserum was raised against the syn-
thetic peptide CSKNVDVEFFKRVRS (MAP1B amino acids 2,360Ð2,373
linked to an NH
 
2
 
-terminal cysteine for convenient linkage to the affinity
matrix; PiChem, Graz, Austria), affinity purified as described (Tgel et
al., 1994) and used at a concentration of 5 
 
m
 
g/ml on immunoblots. The
mouse anti-light chain MAP1B mAb E-12 (Kuznetsov et al., 1986; Sigma
Chemical Co., St. Louis, MO), the mouse anti-heavy chain MAP1B mAb
AA-6 (Boehringer Mannheim GmbH, Mannheim, Germany) and the rat
antiÐHA mAb 3F10 (Boehringer Mannheim GmbH) were used at dilu-
tions of 1:1,000, 1:500 and 1:1,000, respectively. The affinity-purified poly-
clonal rabbit antiÐmyc antibody (Tgel et al., 1998) was used at a concen-
trations of 5 
 
m
 
g/ml on immunoblots and 1 
 
m
 
g/ml for immunofluorescence
microscopy. Intracellular microtubules were decorated with a mixture of 
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mouse anti-tubulin mAbs (B-5-1-2 [Sigma Chemical Co.] at 1:1,000,
TU-01 [Biodesign, Kennebunk, ME] at 1:50, and anti-
 
b
 
-tubulin [Amer-
sham Pharmacia Biotech, Uppsala, Sweden] at 1:25). For the detection of
stress fibers the mouse anti-
 
b
 
-actin mAb AC-15 (Sigma Chemical Co.)
was used at a dilution of 1:400. As secondary antibodies alkaline phos-
phatase-conjugated goat antiÐrabbit, antiÐmouse (both Promega, Heidel-
berg, Germany, dilution 1:7,500), or anti-rat antibodies (dilution 1:5,000,
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) were used
in immunoblots. Donkey antiÐrabbit, antiÐmouse, or antiÐrat antibodies
(Jackson ImmunoResearch Laboratories, Inc.) preadsorbed against se-
rum proteins from other species (in particular those from which the other
primary antibodies used in the same double or triple immunofluorescence
experiment originated) labeled with Texas red, FITC or AMCA were
used at a dilution of 1:100.
 
Cell Culture, Transfection, and Analysis
 
PC12 cells were cultured as described (Greene and Tischler, 1976).
NIH3T3 and PtK2 cells were grown at 37
 
8
 
C in an atmosphere containing
7.5% CO
 
2
 
 in high glucose DME supplemented with 10% FCS in the ab-
sence of tetracycline. 18Ð20 h before transfection cells were seeded onto
coverslips or plates at densities of 45% (NIH3T3) and 66% (PtK2). Tran-
sient transfection was carried out using Lipofectamin (GIBCO BRL) ac-
cording to the manufacturerÕs protocol. The ratio of expression plasmid to
transactivator plasmid was 10:1. The transfection mixture was replaced
with fresh growth medium after 5 h and the cells were incubated for an ad-
ditional 24 h (NIH3T3) or 48 h (PtK2) at 37
 
8
 
C.
For immunofluorescence microscopy PtK2 cells were washed in PBS,
fixed in methanol (
 
2
 
20
 
8
 
C, 10 min), equilibrated in PBS, blocked for 30
min with 3% BSA, incubated with the primary antibodies in 1% BSA for
1 h, washed extensively in PBS, incubated for 1 h with the secondary anti-
body and again washed with PBS. Alternatively, cells were fixed with 4%
paraformaldehyde and 0.2% glutaraldehyde in a buffer containing 5 mM
EGTA, 2 mM MgCl
 
2
 
, and 0.2 M Hepes, pH
 
 
 
7.2. Cells were washed twice
with PBS, incubated for 5 min in 0.1% Triton X-100 in PBS, 3 times for 5
min in 0.5 mg/ml NaBH
 
4
 
 in PBS and 4 times in PBS. Specimens were ana-
lyzed by confocal microscopy (MRC600; Bio-Rad Laboratories, Hercules,
CA) or for triple staining with a cooled CCD-Camera (IP-Lab).
For immunoblot analysis (Sambrook et al., 1989), cells were washed
with PBS, lysed in buffer A, containing 8 M urea, 4% SDS, 0.125 M Tris-
HCl, pH 6.8, 12 mM EDTA, 0.3% DTT, 10 
 
m
 
M benzamidine, 1 mM
PMSF, 2 
 
m
 
M pepstatin, 2 
 
m
 
M aprotinin, 2 
 
m
 
M leupeptin, and 0.002%
bromphenol blue, sonicated, incubated at 65
 
8
 
C for 10 min and subjected
to SDS-PAGE.
For immunoprecipitation experiments all steps starting with the cell ly-
sis were carried out on ice or at 4
 
8
 
C.
 
Cell Lysis Protocol A. 
 
After washing with PBS the cells were lysed on
the plates by incubation for 10 min with lysis buffer B containing 0.5%
Triton X-100, 100 mM NaCl, 100 mM Tris-HCl, pH 7.5, 10 mM EDTA,
0.1 mM DTT, protease inhibitors as described above, and nucleases (0.5
mg/ml DNase [from bovine pancreas, grade II; Boehringer Mannheim
GmbH, Mannheim, Germany] and 0.2 mg/ml RNase [from bovine pan-
creas; Boehringer Mannheim]). The cell lysates were centrifuged for 10
min at 14,000 rpm and the resulting supernatants were transferred to fresh
tubes for further processing.
 
Cell Lysis Protocol B. 
 
The cells were collected by trypsinization and
lysed by Dounce homogenization in lysis buffer C containing PBS, 10 mM
EDTA, 0.1 mM DTT, and protease inhibitors and nucleases as above. The
cell lysates were centrifuged for 10 min at 14,000 rpm and the superna-
tants were transferred to fresh tubes and supplemented with 1/100 vol of
2.5% Tween 20. The resulting supernatants of either cell lysis protocol
were precleared by incubation with 1/10 vol of protein AÐSepharose over
night. After centrifugation for 30 s at 900 rpm in a microcentrifuge the su-
pernatant was transferred into a fresh tube and incubated for 3Ð5 h with
1/10 vol of protein AÐSepharose containing covalently linked (Harlow and
Lane, 1988) affinity-purified anti-myc antibody. The Sepharose-coupled an-
tibody was collected by centrifugation for 30 s at 900 rpm and was washed
twice with a buffer corresponding to the buffer in which the immunopre-
cipitation was performed. After two additional washes with PBS the
Sepharose-coupled antibody was collected by centrifugation as above and
incubated for 5 min at 95
 
8
 
C in an equivalent volume of sample buffer con-
taining 0.125 M Tris-HCl, pH 6.8, 2 mM EDTA, 4% SDS, and 20% glyc-
erol. After centrifugation the supernatant was supplemented with DTT to
a final concentration of 10 mM and incubated for 10 min at 65
 
8
 
C. Samples
were analyzed by SDS-PAGE and immunoblotting as described (Sam-
brook et al., 1989).
Figure 1. Schematic representation of MAP1B domains and
cDNA constructs. Full-length rat MAP1B is depicted as a box
with shading ranging from black to grey in distinct areas indicat-
ing the degree of conservation of the amino acid sequence be-
tween human, rat and mouse in these areas. Black indicates the
highest degree of conservation, overall conservation is 90%. The
positions of the 12 15mer repeats (15mer rep; Noble et al., 1989),
the three major areas of amino acid sequence homology to
MAP1A (MAP1A; Langkopf et al., 1992), and the microtubule
binding domains of the heavy chain (MT binding; Noble et al.,
1989) and the light chain (MT; Zauner et al., 1992) are indicated
as is the site of cleavage of the polyprotein precursor into heavy
and light chain (arrow). The line on top indicates amino acid (aa)
residue positions according to rat full-length MAP1B polyprotein
precursor sequence (Zauner et al., 1992; Liu and Fischer, 1996).
The bottom part depicts the MAP1B proteins encoded by the
cDNA constructs used in this study: the full-length MAP1B
polyprotein precursor (FL; amino acids 1Ð2,459), heavy chain
(HC; amino acids 1Ð2,185), NH2 terminus (NT; amino acids
1Ð508), light chain (LC; amino acids 2,210Ð2,459), COOH termi-
nus (CT; amino acids 2,336Ð2,459), and the microtubule binding
domain of the light chain (MT; amino acids 2,210Ð2,336). In all
cases where the above proteins were epitope tagged by either the
myc- or the HA-tag, the tags were attached to the COOH termini
of the proteins. The abbreviations given in parentheses corre-
spond to those used in labeling of the subsequent figures.
Figure 2. Proteolytic processing of MAP1B ectopically expressed
in nonneuronal cells. Total lysates of NIH3T3 (3T3) and PtK2
cells transfected with the indicated constructs and a lysate of non-
transfected PC12 cells were fractionated by SDS-PAGE on a
10% gel and analyzed by immunoblotting using antibodies to the
light chain (anti-LC) or the myc-tag (anti-Myc). FL, untagged
full-length MAP1B; LC, untagged light chain; FL-Myc, myc-
tagged full-length MAP1B; LC-Myc, myc-tagged light chain. Mo-
lecular mass markers are indicated on the right. 
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Results
 
Correct Proteolytic Processing of Ectopically Expressed 
MAP1B in Nonneuronal Cells
 
To identify domains of MAP1B that might modify the
properties of cellular microtubules or might interact with
other cytoskeletal components we chose to express full-
length MAP1B, the separate heavy and light chains, and
potential subdomains (Fig. 1) in PtK2 and NIH3T3 cells.
These cells express little or no endogenous MAP1B and
thus permit the investigation of MAP1B domains without
the interference of endogenous MAP1B heavy and light
chains. To verify that MAP1B is processed correctly into
heavy and light chain in these nonneuronal cells we ex-
pressed myc-tagged and untagged full-length rat MAP1B
in PtK2 and NIH3T3 cells and analyzed the electro-
phoretic mobility of the resulting light chains on immuno-
blots (Fig. 2). In NIH3T3 cells the ectopic expression of
untagged full-length MAP1B led to the generation of a
protein reactive with the light chainÐspecific antibody that
was indistinguishable in its electrophoretic mobility from
the endogenous light chain expressed in PC12 cells (Fig. 2,
lanes 
 
1
 
 and 
 
2
 
). Expression of myc-tagged full-length
MAP1B in NIH3T3 or PtK2 cells yielded a slightly larger
protein that was detected with antibodies to the light chain
or the myc-tag (Fig. 2, lanes 
 
5Ð10
 
). This slight increase in
size was expected from the addition of the 14Ðamino acid
long myc-tag. On separate gels we analyzed generation of
the heavy chain in these transfected cells using a heavy
chain specific antibody (not shown). From these experi-
ments we estimated that at least 50 and 90% of the ectopi-
cally expressed full-length MAP1B was processed in PtK2
and NIH3T3 cells, respectively.
Since the exact NH
 
2
 
 terminus of the light chain is not
known, we initially expressed three candidate constructs in
NIH3T3 cells, encoding amino acids 2,185Ð2,459, 2,210Ð
2,459, or 2,222Ð2,459 (numbers referring to the amino acid
position in the full-length polyprotein precursor). The con-
struct encoding untagged amino acids 2,210Ð2,459 gave
rise to a protein that reacted with the light chainÐspecific
mAb E-12 (Kuznetsov et al., 1986) and was indistinguish-
able in size from the endogenous light chain expressed in
PC12 cells (Fig. 2, lanes 
 
1
 
 and 
 
3
 
). In addition, the protein
encoded by this construct corresponds in its NH
 
2
 
 terminus
to the NH
 
2
 
 terminus of the MAP1B light chain as pre-
dicted by amino acid sequence data (Hammarback et al.,
1991). Therefore, this protein comprising amino acids
2,210Ð2,459 is henceforth referred to as the light chain of
MAP1B in this report. The construct encoding amino ac-
Figure 3. The MAP1B light chain binds to microtubules in vivo and induces changes in the microtubule network. PtK2 cells transfected
with myc-tagged full-length MAP1B (A and B) or myc-tagged light chain (C and D) were analyzed by double immunofluorescence mi-
croscopy using antibodies to the myc-tag (A and C) and tubulin (B and D). The cellular arrangement of microtubules remained un-
changed in cells expressing full-length MAP1B. Cells expressing light chain only showed binding of the light chain to microtubules and
displayed wavy microtubules concentrated in areas about halfway between the nucleus and the periphery. Bar, 10 mm. 
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ids 2,185Ð2,459 gave rise to a protein larger than the en-
dogenous light chain of PC12 cells, and the construct en-
coding amino acids 2,222Ð2,459 gave rise to a protein that
did not react with the light chainÐspecific mAb E-12 (data
not shown), indicating that the E-12 epitope is localized at
the NH
 
2
 
 terminus of the light chain between amino acids
2,210 and 2,222. The faint band detected with anti-light
chain antibody in untransfected NIH3T3 and PtK2 cells
(Fig. 2, lanes 
 
4
 
 and 
 
7
 
) may have represented endogenous
light chain or a related protein expressed in these cells at
low levels (Hammarback et al., 1991; Domnguez et al.,
1994).
 
The Light Chain of MAP1B Has Microtubule 
Stabilizing Activity
 
It has previously been shown by in vitro cosedimentation
assays that one of the two microtubule binding domains of
MAP1B is located between amino acids 2,210 and 2,331
(Zauner et al., 1992). This region of the full-length poly-
protein precursor constitutes the NH
 
2
 
-terminal half of the
light chain. Expression of the light chain in PtK2 cells re-
vealed that it can bind to microtubules in vivo and that it
can induce a change in cellular microtubule arrangement
(Fig. 3, 
 
C
 
 and 
 
D
 
). Many microtubules assumed a wavy ap-
pearance with a relatively high density of closely spaced
wavy microtubules about halfway between the nucleus
and the periphery. This altered microtubule arrangement
was characteristic for the MAP1B light chain and has not
been observed with other MAPs such as MAP1A (Crav-
chik et al., 1994), MAP2 (Weisshaar et al., 1992), or MAP4
(Olson et al., 1995; Nguyen et al., 1997). Full-length
MAP1B consisting of heavy and light chain did not induce
this change in microtubule appearance (Fig. 3, 
 
A
 
 and 
 
B
 
).
Full-length MAP1B displayed diffuse and fibrillar local-
ization, the latter colocalizing with microtubules, consis-
tent with published observations (Noble et al., 1989).
We next analyzed whether the MAP1B light chain can
induce microtubule stabilization by conducting experi-
ments with nocodazole. Nocodazole prevents the de novo
polymerization of tubulin heterodimers and thus leads to
depolymerization of microtubules owing to their dynamic
instability (Hoebeke et al., 1976). In nontransfected cells
and in cells transfected with full-length MAP1B compris-
ing heavy and light chain nocodazole treatment at 10 
 
m
 
g/
ml for 1 h before fixation caused the depolymerization of
most microtubules and led to a diffuse cytoplasmic tubulin
staining with the occasional detection of remaining micro-
tubules (Fig. 4, 
 
A
 
 and 
 
B
 
). Only 
 
z
 
5% of cells displayed sta-
ble microtubules. In contrast, when the light chain on its
Figure 4. The MAP1B light chain protects microtubules against the effects of nocodazole. PtK2 cells transfected with myc-tagged full-
length MAP1B (A and B) or the myc-tagged MAP1B light chain (C and D) were treated with nocodazole (1 h, 10 mg/ml) and then ana-
lyzed by double immunofluorescence microscopy using antibodies to the myc-tag (A and C) and tubulin (B and D). Microtubules were
depolymerized in nontransfected cells and in cells expressing full-length MAP1B. In cells expressing the light chain, microtubules with
the characteristic light chainÐinduced appearance were present despite treatment with nocodazole. Bar, 10 mm. 
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own was ectopically expressed, stabilization of microtu-
bules against the effects of nocodazole was observed in
about 60% of the cells (Fig. 4, 
 
C
 
 and 
 
D
 
). In addition to
stabilization, the light chain induced the characteristic
changes of the microtubule network with many microtu-
bules assuming a wavy, sometimes looped appearance.
These results show that the light chain is capable of induc-
ing microtubule stabilization and that this light chain activ-
ity is inhibited in the presence of the heavy chain.
We also tested the effect of taxol in cells expressing
MAP1B light chain. Taxol reduces the critical concentra-
tion of tubulin polymerization and induces de novo poly-
merization of centrosome-independent microtubules (de
Brabander et al., 1981). Treatment of cells with 5 
 
m
 
M taxol
for 7 h before fixation induced multiple centrosome-inde-
pendent microtubule bundles at the periphery of non-
transfected cells, and expression of full-length MAP1B did
not prevent this effect of taxol (Fig. 5, 
 
A
 
 and 
 
B
 
). In
contrast, in cells expressing the light chain only taxol
treatment failed to induce formation of centrosome-inde-
pendent, peripheral microtubule bundles. Instead, micro-
tubules again displayed the characteristic light chainÐ
induced wavy and looped appearance (Fig. 5, 
 
C
 
 and 
 
D
 
).
Thus, the results of both, nocodazole or taxol treatment of
cells indicated that the MAP1B light chain can inhibit mi-
crotubule depolymerization.
 
The MAP1B Light Chain Binds to the Heavy
Chain and Can Oligomerize via Its COOH-terminal 
MAP1A Homology Domain
 
The results presented above demonstrated that the MAP1B
light chain had distinct effects on the morphological ap-
pearance and stability of microtubule networks as long as
it was expressed in the absence of the heavy chain. Coex-
pression of heavy and light chains by transfecting cells
with a construct encoding the full-length polyprotein pre-
cursor that is cleaved to give rise to heavy and light chains
had little or no effect on microtubules, suggesting that the
heavy chain might inhibit light chain activity. Similar re-
sults were obtained when heavy and light chain were coex-
pressed in the same cells from two separate constructs, one
encoding a myc-tagged heavy chain and the other encod-
ing an HA-tagged light chain. Cells coexpressing both pro-
teins displayed both diffuse and fibrillar localization of
heavy and light chain (Fig. 6, 
 
A
 
 and 
 
B
 
), reminiscent of
Figure 5. The MAP1B light chain protects microtubules against the effects of taxol. PtK2 cells transfected with myc-tagged full-length
MAP1B (A and B) or the myc-tagged MAP1B light chain (C and D) were treated with taxol (7 h, 5 mM) and then analyzed by double
immunofluorescence microscopy using antibodies to the myc-tag (A and C) and tubulin (B and D). Microtubules formed short, cen-
trosome-independent bundles in nontransfected cells and in cells expressing full-length MAP1B (B and D, arrows). As was observed in
the absence of taxol (Fig. 3 A) full-length MAP1B displayed diffuse cytoplasmic localization in addition to colocalization with
taxol-induced microtubule bundles indicative of its weak association with microtubules. In cells expressing the light chain microtubules
displayed the characteristic light chainÐinduced appearance despite treatment with taxol (D, arrowheads). Bar, 10 mm.Tgel et al. Functional Domain Analysis of MAP1B 701
what had been observed in cells expressing heavy and light
chains generated by precursor cleavage (Fig. 3 A). Triple
immunofluorescence analysis revealed that the intracellu-
lar fibers decorated by anti-myc and anti-HA antibodies
were microtubules (Fig. 6 C). Thus, heavy and light chain
colocalized with each other and with microtubules. When
the heavy chain was expressed in the absence of the light
chain, only diffuse staining was observed (Fig. 6 D), indi-
cating that the light chain is necessary for efficient micro-
tubule binding of the heavy chainÐlight chain complex.
Furthermore, no significant changes of microtubule ap-
pearance or stability were observed in cells expressing the
heavy chain only (not shown). In populations of cells coex-
pressing heavy and light chain from separate constructs
(cotransfection at a molar ratio of 2:1) the number of cells
displaying changes in microtubule arrangement or stability
against nocodazole or taxol was reduced to 40% or less
compared with cells expressing the light chain only. These
results provided further evidence that the heavy chain has
little or no effect on its own but can inhibit the effect of the
light chain on microtubule appearance and stability.
An analogous cotransfection experiment was carried
out using a construct encoding an NH2-terminal fragment
of the heavy chain instead of the entire heavy chain. This
fragment contained the NH2-terminal MAP1A homology
domain of the MAP1B heavy chain but lacked its microtu-
bule binding domain (Fig. 1). As with the entire heavy
chain, we observed that the NH2 terminus, when ex-
pressed on its own, showed diffuse cytoplasmic distribu-
tion (Fig. 7 D) and had no effect on microtubules (not
shown). In contrast, when the NH2 terminus was coex-
pressed with the light chain, NH2 terminus (Fig. 7 A) and
light chain (Fig. 7 B) colocalized on microtubules (Fig. 7
C). In addition, both proteins displayed diffuse cytoplas-
mic distribution (Fig. 7, A and B) but apparently to a
lesser extend than when the entire heavy chain and the
light chain were coexpressed (compare Fig. 7, A and B
with Fig. 6, A and B). In populations of cells coexpressing
Figure 6. The light chain mediates microtubule binding of the MAP1B heavy chainÐlight chain complex. PtK2 cells cotransfected with
cDNA constructs encoding the myc-tagged heavy chain (HC-Myc) and the HA-tagged light chain (LC-HA; AÐC) at a molar ratio of
0.8:1, or transfected with a single construct encoding the myc-tagged heavy chain (D) were analyzed by triple immunofluorescence mi-
croscopy using antibodies to the myc-tag (A and D), the HA-tag (B), and tubulin (C). In cells expressing only the heavy chain, the pro-
tein showed diffuse cytoplasmic distribution (D). In contrast, in cells coexpressing heavy and light chain, both proteins displayed not
only diffuse cytoplasmic distribution but also fibrillar staining that colocalized with microtubules (AÐC, arrows). This pattern of intracel-
lular distribution reflects the weak microtubule association of the MAP1B heavy chainÐlight chain complex. Bar, 10 mm.The Journal of Cell Biology, Volume 143, 1998 702
NH2 terminus and light chain (cotransfection at a molar
ratio of 4:1) the number of cells displaying stabilization of
microtubules against nocodazole was reduced to 66%
compared with cells expressing the light chain alone.
Taken together these results indicated that the light chain
can form a complex with the NH2-terminal 508 amino ac-
ids of the heavy chain and that this complex can bind to
microtubules via the microtubule binding domain of the
light chain. Binding of the NH2 terminus led to a reduction
of the light chains activity to induce changes in microtu-
bule appearance and stability but did not appear to block
its binding to microtubules.
To confirm heavy chainÐlight chain interactions ob-
served by immunofluorescence microscopy and to more
precisely define the interacting domains we performed coim-
munoprecipitation experiments using lysates of NIH3T3
cells cotransfected with constructs encoding the myc-
tagged NH2 terminus of the heavy chain and the HA-
tagged COOH terminus of the light chain. The latter
comprises the most COOH-terminal MAP1A homology
domain of MAP1B (Fig. 1). Lysates of transfected cells
were subjected to immunoprecipitation using anti-myc an-
tibodies and the precipitates were analyzed by immuno-
blotting for the presence of NH2 terminus and COOH ter-
minus using antibodies directed against the myc- and the
HA-tag, respectively. Precipitation of the NH2-terminal
fragment with anti-myc antibodies (Fig. 8, lane 1) led to
the coprecipitation of the COOH terminus of the light
chain that was detected on immunoblots using anti-HA
antibodies (Fig. 8, lane 3). From lysates of control cells ex-
pressing only the COOH terminus of the light chain (Fig.
8, lane 4) this fragment could not be precipitated with the
anti-myc antibody (Fig. 8, lane 5) demonstrating the speci-
ficity of precipitation. Equivalent results were obtained
when the experiment was performed with HA- instead of
myc-tagged NH2 terminus and myc- instead of HA-tagged
COOH terminus. Thus, we have narrowed down the loca-
tion of MAP1B heavy chainÐlight chain interaction do-
mains to the NH2-terminal 508 amino acids of the heavy
chain and the COOH-terminal 125 amino acids of the light
chain.
We also investigated whether individual light chain mol-
ecules can directly or indirectly associate with each other,
a feature that could have important implications for their
mechanism of action. NIH3T3 fibroblasts were cotrans-
fected with two constructs both encoding the COOH ter-
minus of the light chain either in its HA-tagged or in its
myc-tagged (Fig. 9). After transient expression of the con-
structs the cells were lysed and the lysates were subjected
to immunoprecipitation using the anti-myc antibody. The
precipitates were analyzed on immunoblots using either
the anti-myc antibody (Fig. 9, lane 1) or the anti-HA anti-
body (Fig. 9, lane 2). This analysis showed that both pro-
teins were expressed and that precipitation of the myc-
tagged COOH terminus with anti-myc antibodies led to
coprecipitation of the HA-tagged COOH terminus. For
controls, cells were cotransfected with constructs encoding
the HA-tagged COOH terminus and the myc-tagged mi-
crotubule binding domain of the light chain. Immunopre-
cipitation with the anti-myc antibody led to the precipita-
tion of the myc-tagged microtubule binding domain (Fig.
9, lane 4) but not the HA-tagged COOH terminus (Fig. 9,
lane 5) despite the presence of this protein in the extracts
(Fig. 9, lane 3). This demonstrated the specificity of copre-
cipitation as the anti-myc antibody precipitated the HA-
Figure 7. The light chain binds in vivo to the NH2-terminus of the
heavy chain. PtK2 cells cotransfected with constructs encoding
the HA-tagged NH2 terminus of the heavy chain (NT-HA) and
the myc-tagged light chain (NT-HA 1 LC-Myc; AÐC) at a molar
ratio of 2:1, or transfected with a single construct encoding the
HA-tagged NH2 terminus (D) were analyzed by triple immuno-
fluorescence microscopy using antibodies to the HA-tag (A and
D), the myc-tag (B), and tubulin (C). In cells expressing only the
NH2 terminus of the heavy chain, the protein showed diffuse cy-
toplasmic distribution (D). In cells coexpressing NH2 terminus
and light chain both proteins displayed fibrillar staining that colo-
calized with microtubules (AÐC, arrows) in addition to diffuse cy-
toplasmic distribution. Bar, 10 mm.
Figure 8. Domains responsible for the mutual interaction of
MAP1B heavy and light chains. NIH3T3 cells were cotransfected
with constructs encoding the myc-tagged NH2 terminus (N Ter-
minus) and the HA-tagged COOH terminus (C Terminus; lanes
1Ð3), or were transfected with a single construct encoding the
HA-tagged COOH terminus (lanes 4 and 5) as indicated. Lysates
of transfected cells were prepared by protocol A (see Materials
and Methods) and analyzed by immunoblotting, either directly
(E) or after immunoprecipitation (IP) using the anti-myc anti-
body. The blot was probed with antibodies directed against the
HA-tag (HA) or the myc-tag (Myc) as indicated. Positions of the
NH2 and COOH terminus are indicated. Molecular mass markers
are shown on the right.Tgel et al. Functional Domain Analysis of MAP1B 703
tagged COOH terminus only when cells had been cotrans-
fected with myc-tagged COOH terminus (Fig. 9, lane 2)
but not with other myc-tagged proteins (Fig. 9, lane 5). At
the same time it showed the specificity of the interaction
of the COOH terminus with itself but not with other co-
expressed proteins. Similar results were obtained when
coprecipitation experiments were performed using cells
coexpressing the entire untagged light chain and the myc-
tagged COOH terminus, ruling out that light chain oligo-
merization is artificially induced by truncation or epitope
tagging of the protein (not shown). Moreover, we ob-
served colocalization of the untagged light chain and the
myc-tagged COOH terminus by immunofluorescence mi-
croscopy (not shown) providing independent evidence for
light chain oligomerization. Thus, our experiments dem-
onstrated that light chain molecules can form complexes
with each other by specific interaction through a domain
located in their COOH-terminal 125 amino acids.
Binding of the MAP1B Light Chain COOH Terminus to 
Actin Stress Fibers
Amino acid sequence comparison of MAP1B and MAP1A
revealed two remarkable features about the COOH termi-
nus of the MAP1B light chain. First, this region of MAP1B
is among those highest conserved between human, mouse
and rat (Fig. 1) and secondly, this region comprises one of
the three longer stretches of homology between MAP1B
and MAP1A (Fig. 1; Langkopf et al., 1992). To investigate
whether this part of the light chain contains functional do-
mains in addition to those identified above we transiently
expressed the COOH terminus in PtK2 cells and analyzed
its intracellular localization by immunofluorescence mi-
croscopy (Fig. 10). In addition to diffuse intracellular dis-
tribution we observed colocalization of the myc-tagged
COOH terminus with actin stress fibers (Fig. 10, A and B).
Decoration of the stress fibers by the anti-myc antibody
occurred in a punctate manner, regardless of whether the
cells had been fixed with methanol or paraformaldehyde
before incubation with the antibody. Anti-myc staining
was not detected at the most peripheral segments of actin
stress fibers indicating that binding of the COOH terminus
was reduced or absent in these regions.
Since the COOH terminus of the light chain harbors the
domain for the binding of the light chain to the NH2 termi-
nus of the heavy chain (Fig. 8) we examined whether bind-
ing of the COOH terminus to the heavy chain or to stress
fibers interfere with each other. PtK2 cells were cotrans-
fected with constructs encoding the HA-tagged NH2
terminus of the heavy chain and the myc-tagged COOH
terminus of the light chain and analyzed by triple immu-
nofluorescence microscopy using anti-HA and anti-myc
antibodies (Fig. 10, C and D), and anti-actin antibodies
(not shown). The COOH terminus again displayed punc-
tate localization on stress fibers in addition to diffuse cy-
toplasmic distribution. Remarkably, the NH2 terminus of
the heavy chain, which when expressed on its own dis-
played diffuse cytoplasmic distribution (Fig. 7 D), was
found to colocalize with the COOH terminus on stress fi-
bers. This observation confirmed our results obtained by
coimmunoprecipitation analysis (Fig. 8) and showed that
the COOH terminus of the light chain can bind to the NH2
terminus of the heavy chain in vivo. Furthermore, these
results demonstrated that binding of the COOH terminus
to the heavy chain and to stress fibers were not mutually
exclusive and that the COOH terminus can target the oth-
erwise diffusely distributed MAP1B NH2 terminus to
stress fibers.
Discussion
Previous studies on the effects of MAP1B on microtubule
organization and function have used the MAP1B protein
complex consisting of heavy and light chains. In these
studies the observed effects of MAP1B on microtubule
stabilization were weak when compared with those of
MAP2 (Lewis et al., 1989; Noble et al., 1989; Takemura et
al., 1992; Weisshaar et al., 1992; LeClerk et al., 1993; Weis-
shaar and Matus, 1993; Pedrotti and Islam, 1995) and assay
systems for a molecular analysis of MAP1B function based
on induction of dramatic phenotypic changes in cellular
microtubule networks have not been described previously.
In the present study we attempted to identify functional
domains and possible activities of the MAP1B light chain
without the interference by the heavy chain. For this pur-
pose we chose to use as the experimental system cultured
nonneuronal cells that have a low background of endoge-
nous MAP1B. This enabled us to study effects of the light
chain when it is not complexed by the heavy chain. In this
system we were able to show for the first time that the
light chain of MAP1B indeed has function(s) on its own. It
bound to microtubules in vivo and effectively stabilized
microtubules in a manner distinct from other microtubule-
stabilizing proteins or drugs. We have also demonstrated
that light chains can oligomerize and have narrowed down
the regions of MAP1B necessary for light chainÐheavy
chain interaction. In addition, we have identified a novel
functional domain of the MAP1B light chain that mediates
binding of the COOH terminus of the light chain to actin
stress fibers. Our results show that many activities of
MAP1B previously observed in in vivo and in vitro assays
using the entire MAP1B protein complex can be attrib-
Figure 9. MAP1B light
chains can interact through a
domain in the COOH termi-
nus. NIH3T3 cells were co-
transfected with constructs
encoding the COOH termi-
nus in its HA-tagged (CT-
HA) or myc-tagged (CT-
Myc) form (lanes 1 and 2) or
were cotransfected with con-
structs encoding the HA-
tagged COOH terminus and
the myc-tagged microtubule binding domain (MT-Myc) of the
light chain (lanes 3Ð5). Lysates of transfected cells were prepared
by protocol B (see Materials and Methods) and analyzed on an
immunoblot either directly (E) or following immunoprecipitation
(IP) using the anti-myc antibody. The blot was probed with anti-
bodies directed against the HA-tag (HA) or the myc-tag (Myc) as
indicated. The positions of the COOH terminus and the microtu-
bule binding domain on the blot are indicated. Molecular mass
markers are shown on the right.The Journal of Cell Biology, Volume 143, 1998 704
uted to the light chain and are unmasked and enhanced by
expressing the light chain in the absence of the heavy
chain. Apart from the microtubule binding domain, all
light chain activities identified here were found to be local-
ized in the COOH terminus that is among those regions of
MAP1B most highly conserved in evolution. This region
of z120 amino acid residues is also found in the COOH
terminus of the light chain of the related protein MAP1A
(Langkopf et al., 1992). On the other hand, the NH2-termi-
nal half of the MAP1B light chain that contains the micro-
tubule binding domain (Zauner et al., 1992) has no corre-
sponding counterpart in the light chain of MAP1A. These
results suggest that the light chains of MAP1B and
MAP1A might have overlapping but distinct sets of activi-
ties.
Expression of the MAP1B light chain induced a unique
change in the appearance of microtubules that had not
been observed previously with any other MAP including
MAP2 (Weisshaar et al., 1992), MAP4 (Olson et al., 1995;
Nguyen et al., 1997), and MAP1A (Cravchik et al., 1994).
This distinctness of MAP1B light chain effects is reflected
by the primary structure of its microtubule binding do-
main, a basic region without pronounced repetitive motifs,
lacking sequence homology to the microtubule binding
domains of other MAPs (Zauner et al., 1992). Microtu-
bules in light chainÐexpressing cells were stabilized against
the effects of nocodazole (Fig. 4), but did not form the
straight peripheral bundles seen in the presence of MAP2,
indicating that MAP1B does not have microtubule nucle-
ating activity. This interpretation is consistent with results
obtained in in vitro assays that demonstrated that MAP1B
has a weaker nucleating activity than MAP2 (Pedrotti et
al., 1996a). Instead of forming peripheral bundles, many
microtubules in MAP1B light chainÐexpressing cells dis-
played a wavy appearance, perhaps due to excessive
length. This observation suggests that microtubules were
stabilized but retained considerable flexibility. The wavy
appearance of microtubules in the presence of the MAP1B
Figure 10. Interaction of the MAP1B light chain COOH terminus with actin stress fibers. PtK2 cells were transfected with a construct
encoding the myc-tagged COOH terminus of the light chain (CT-Myc; A and B) and were analyzed by double immunofluorescence mi-
croscopy using antibodies to the myc-tag (A) and actin (B). In a separate experiment cells were cotransfected with constructs encoding
the myc-tagged COOH terminus of the light chain and the HA-tagged NH2 terminus of the heavy chain (CT-Myc 1 NT-HA; C and D)
and were analyzed by triple immunofluorescence microscopy using antibodies to the HA-tag (C), the myc-tag (D), and actin (not
shown). The COOH terminus when expressed on its own or in the presence of the NH2 terminus was found to localize on stress fibers in
a punctate manner (A and D). In cells coexpressing NH2 terminus and the COOH terminus both proteins displayed stress fiber localiza-
tion (C and D) in addition to diffuse cytoplasmic distribution. Bar, 10 mm.Tgel et al. Functional Domain Analysis of MAP1B 705
light chain is of particular interest for two reasons. First, it
has been demonstrated that MAP1B induces the forma-
tion of long, ÒbendyÓ microtubules in vitro and that this
property of MAP1B distinguishes it from MAP1A and
MAP2 (Pedrotti et al., 1996a). Our results obtained in vivo
in PtK2 cells are consistent with these findings. More im-
portantly, bent microtubules and microtubule loops have
been detected in growth cones of extending neurites in
vivo (Tsui et al., 1984; Sabry et al., 1991; Tanaka and Kir-
schner, 1991; Challacombe et al., 1996) where they are be-
lieved to be instrumental in growth cone migration and
guidance. The detection of phosphorylated MAP1B at
high concentrations in distal axons and growth cones has
led to the suggestion that growth cones might be an im-
portant site of action of MAP1B (Tanaka et al., 1992;
Black et al., 1994; Boyne et al., 1995; Bush et al., 1996).
Taken together, these observations raise the possibility
that MAP1B, acting in growth cones, might be involved in
the induction of bent microtubules and microtubule loops
in vivo. Our finding that the MAP1B light chain can in-
duce wavy microtubules in PtK2 cells lends support to this
hypothesis. MAP1B light chain effects on microtubules
also differed from those of the microtubule stabilizing
drug taxol (de Brabander et al., 1981). Expression of the
MAP1B light chain prevented taxol-induced formation of
centrosome-independent microtubule bundles, indicating
that in the presence of the light chain the concentration of
free tubulin heterodimers was lowered below the critical
concentration for taxol-induced tubulin polymerization. It
will be interesting to investigate whether the MAP1B light
chainÐinduced stabilization of microtubules differs from
taxol stabilization in that it might be resistant to changes
in microtubule dynamics taking place when cells enter mi-
tosis.
We have obtained evidence that MAP1B light chains
can form dimers or oligomers either directly or through
binding to additional factors (Fig. 9). Our results have
been obtained in the absence of the MAP1B heavy chain
and the question arises whether light chain oligomeriza-
tion can at all occur in neurons where the light chain is ex-
pressed together with the heavy chain. However, it has
been shown previously that the MAP1B protein complex
purified from rat or calf brain contains a two- to threefold
molar excess of light chains over the heavy chain (Schoen-
feld et al., 1989; Pedrotti et al., 1996b). This is consistent
with the interpretation that light chain oligomerization
could occur in the presence of heavy chain in neurons and
glial cells. Light chain dimers or oligomers could have mi-
crotubule cross-linking activity, leading to the formation
of microtubule bundles. However, at this point we have no
clear indication that microtubules, which sometimes ap-
peared closely spaced in light chainÐexpressing cells, form
bundles. Although it has been demonstrated that MAP1B
can cross-link microtubules in vivo and in vitro (Hirokawa
et al., 1985; Sato-Yoshitake et al., 1989), in previous stud-
ies using full-length MAP1B no microtubule bundling ac-
tivity was observed in NIH3T3, HeLa or COS cells (Noble
et al., 1989; Takemura et al., 1992) in agreement with the
results shown here. It is tempting to speculate that oligo-
merization of the light chain might have an alternative
purpose. Bringing together two or more microtubule bind-
ing domains could mimic the arrangement found in other
MAPs, where three or more microtubule binding domains
are found in tandem on a single polypeptide chain. If light
chain oligomerization were necessary for efficient binding
to single or multiple microtubules through closely spaced
binding domains, binding of the light chains to microtu-
bules should be reduced under conditions where oligomer-
ization is inhibited. In preliminary experiments we found
that binding of the light chain to microtubules can be in-
hibited by simultaneous overexpression of the COOH ter-
minus of the light chain (not shown). The COOH terminus
contains the oligomerization domain but lacks the micro-
tubule binding site and thus might prevent the formation
of light chain oligomers containing multiple microtubule
binding sites by replacing one or more light chains in the
oligomers.
It has previously been shown that the MAP1B light
chain binds to a 120-kD fragment of the NH2 terminus of
the heavy chain that includes the NH2-terminal microtu-
bule binding site (Kuznetsov et al., 1986). Here we have
further narrowed down the sites of interaction between
heavy and light chains. Coexpression of the light chain and
a fragment of the NH2 terminus of the heavy chain (amino
acids 1Ð508) that lacks the NH2-terminal microtubule
binding domain revealed that the light chain can bind to
this fragment in vivo (Fig. 7). Further experiments showed
that the domain on the light chain responsible for interac-
tion with the heavy chain is located in its COOH-terminal
120 amino acids (Figs. 8 and 10). Both regions of MAP1B
shown here to be sufficient for heavy chainÐlight chain in-
teraction contain long stretches of homology to MAP1A
(Fig. 1). Our findings raise the possibility that the MAP1A
homology domains in the NH2 terminus of the heavy chain
and the COOH terminus of the light chain of MAP1B are
in fact the heavy chainÐlight chain interaction domains.
This interpretation is supported by reports locating the
light chain binding domain on the MAP1A heavy chain in
the corresponding NH2-terminal region of MAP1A and it
has been shown that the heavy chain of MAP1A can bind
the light chain of MAP1B (Schoenfeld et al., 1989).
Earlier studies using purified MAP1B in in vitro experi-
ments have shown that MAP1B and in particular the
MAP1B light chain can bind to actin filaments (Fujii et al.,
1993; Pedrotti and Islam, 1996). Here we were able to con-
firm and extend these results by demonstrating that bind-
ing to actin stress fibers can occur in vivo (Fig. 10). In addi-
tion, we found that the COOH terminus of the light chain
can efficiently target the NH2 terminus of the heavy chain
to stress fibers, suggesting that heavy chainÐlight chain in-
teraction per se might not be incompatible with binding of
MAP1B to actin filaments. Our results indicate that the
domain responsible for binding to stress fibers is located in
the 120 COOH-terminal amino acids of the light chain. As
pointed out above, the COOH terminus of the MAP1B
light chain corresponds to one of the three long MAP1A
homology domains of MAP1B. Interestingly, actin binding
has also been reported for MAP1A and its light chain
(Fujii et al., 1993; Pedrotti and Islam, 1996). At this point it
is not clear whether binding of the COOH terminus to
stress fibers is due to an interaction with actin or with actin
filament-associated proteins. The amino acid sequence of
the COOH terminus does not contain an actin binding site
of the type found in spectrin and dystrophin (Matsudaira,The Journal of Cell Biology, Volume 143, 1998 706
1991). On the other hand, we observed that the COOH
terminus did not bind to the most peripheral segments of
stress fibers, suggesting that stress fiber-associated pro-
teins might be involved in mediating or inhibiting binding.
Our experiments revealed that the COOH-terminal frag-
ment of the MAP1B light chain can associate with stress
fibers whereas the entire light chain consisting of the NH2-
terminal microtubule binding domain and the COOH ter-
minus could not be detected on stress fibers and was found
to colocalize with microtubules instead. One possible ex-
planation for this observation is that the COOH-terminal
actin filament binding domain is masked in the full-length
protein and as a consequence the protein binds to micro-
tubules through the microtubule binding domain. If the
NH2-terminal half of the light chain is removed, the
COOH-terminal domain could be exposed leading to as-
sociation with stress fibers. Such results have been ob-
tained, for example, for ezrin, an 80-kD actin binding pro-
tein that mediates plasma membrane-actin cytoskeleton
interactions (Algrain et al., 1993). Subsequently it has
been shown that masking of the COOH-terminal actin
binding site in ezrin by the NH2 terminus is part of the reg-
ulatory mechanism controlling ezrin activity. In vivo, un-
masking of the actin binding domain of ezrin is achieved
by phosphorylation. A similar mechanism could be in-
volved in MAP1B light chain action. It has recently been
demonstrated that phosphorylation of MAP1B on sites yet
to be identified influences its binding to microfilaments in
vitro (Pedrotti and Islam, 1996).
The comparison of MAP1B light chain activities in the
absence and presence of the heavy chain revealed that
binding to microtubules and microtubule stabilization
were greatly reduced in the presence of the heavy chain
(Figs. 3Ð5). This inhibition was not due to incomplete pro-
cessing of the polyprotein precursor that was used in these
experiments as a convenient means to express both heavy
and light chain in the same cell, because similar results
were obtained when heavy and light chain were coex-
pressed in the same cell from separate constructs. We hy-
pothesize that one function of he heavy chain might be to
act as a regulatory subunit to control light chain activity.
We found that heavy chainÐlight chain interaction does
not per se inhibit light chain microtubule binding capacity
and only partially reduces its microtubule stabilization
activity. Thus, a separate regulatory domain could be
present in the heavy chain and might act on bound light
chains. In our experiments we were able to observe light
chain activity, because we expressed the light chain in the
absence of this hypothetical regulatory domain. Under
physiological conditions, when heavy and light chains are
present at similar levels other regulatory mechanisms
would need to be involved. There is ample evidence in the
literature that in brain and cultured neurons there is a
large soluble cytoplasmic pool of MAP1B (Bloom et al.,
1985; Daz-Nido et al., 1990; Tanaka et al., 1992; Ulloa et
al., 1993a; Keating and Asai, 1994) and that binding of
MAP1B to microtubules in vivo (Daz-Nido et al., 1990;
Ulloa et al., 1993a,b) and to microfilaments in vitro
(Pedrotti and Islam, 1996) is regulated by phosphoryla-
tion. It is conceivable that phosphorylation of MAP1B at
specific sites leads to a conformational change that liber-
ates the light chain from the inhibitory influence of the
regulatory domain. This would provide neurons with a
mechanism to regulate a transient association of soluble
MAP1B with microtubules and thus transient microtubule
stabilization and perhaps interaction with actin filaments
in individual cellular and axonal compartments in re-
sponse to extra- and/or intracellular signals (Pigino et al.,
1997).
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